Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)
https://www.facingourrisk.org/research-clinical-trials/study/177/androgen-suppression-with-abiraterone-leuprolide-parp-inhibitor-and-stereotactic-radiotherapy-in-prostate-cancer-asclepius
Clinicaltrials.gov identifier:
NCT04194554 (https://clinicaltrials.gov/show/NCT04194554)
Newly diagnosed prostate cancer grade group 3-5
About the Study
This study is no longer enrolling patients.
This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.
This Study is Open To:
This study is no longer enrolling patients.
This Study is Not Open To:
This study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.